Pyrazinamide Resistance Mechanisms in Mycobacterium Tuberculosis

Pyrazinamide is a cornerstone of tuberculosis therapy due to its unique activity against persistent Mycobacterium tuberculosis. Resistance arises predominantly through mutations in the pncA gene encoding pyrazinamidase, which prevent conversion of the prodrug to its active form, pyrazinoic acid. However, a spectrum of alternative mechanisms has emerged, including secondary mutations in rpsA that alter drug binding to ribosomal protein S1, and mutations in panD that safeguard coenzyme A pools. Structural genomic variations and subpopulations with large deletions in pncA can evade conventional molecular diagnostics. Phenotypic heterogeneity, lineage-specific markers and compensatory cell envelope changes contribute further complexity. These insights inform the development of more robust diagnostics, novel therapeutics targeting resistance pathways and optimised regimens to curb the global threat posed by drug-resistant TB.

Research from Nature Portfolio

Recent studies have mapped the full spectrum of pncA polymorphisms by saturating mutagenesis and functional screening, revealing over 300 distinct substitutions that impair pyrazinamidase stability or activity and distribute across the enzyme’s three-dimensional fold. Complementary work has applied graph-based structural modelling to predict the phenotypic impact of pncA variants, achieving over 80 percent accuracy in classifying resistance mutations and guiding interpretation of clinical genomes. Investigations of novel rpsA mutations have combined crystal structures and free energy calculations to demonstrate how alterations in the fourth S1 domain reduce affinity for pyrazinoic acid, identifying specific residues that perturb drug-target interactions and contribute to low-level resistance.

Pyrazinamide Resistance Mechanisms in Mycobacterium Tuberculosis publication trend

The graph below shows the total number of articles in pyrazinamide resistance mechanisms in mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

pncA: Gene encoding nicotinamidase/pyrazinamidase that converts pyrazinamide into its active form, pyrazinoic acid.

rpsA: Gene encoding ribosomal protein S1, a secondary target of pyrazinoic acid involved in trans-translation.

panD: Gene encoding aspartate decarboxylase, essential for biosynthesis of coenzyme A.

Pyrazinoic acid (POA): Active metabolite of pyrazinamide responsible for antibacterial activity.

Phenotypic susceptibility testing: Culture-based assay to determine the growth response of bacteria to antimicrobial concentrations.

References

1. Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics. Drug Resistance Updates (2023).
2. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nature Communications (2017).
3. Structure guided prediction of Pyrazinamide resistance mutations in pncA. Scientific Reports (2020).
4. Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance. Scientific Reports (2019).
5. Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infectious Diseases (2016).
6. Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020. Frontiers in Microbiology (2025).